Suppr超能文献

CD8+ T 细胞未能在病毒扩增后限制停止 ART 后 SIV 的重新激活。

CD8+ T cells fail to limit SIV reactivation following ART withdrawal until after viral amplification.

机构信息

Vaccine and Gene Therapy Institute and.

Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.

出版信息

J Clin Invest. 2021 Apr 15;131(8). doi: 10.1172/JCI141677.

Abstract

To define the contribution of CD8+ T cell responses to control of SIV reactivation during and following antiretroviral therapy (ART), we determined the effect of long-term CD8+ T cell depletion using a rhesusized anti-CD8β monoclonal antibody on barcoded SIVmac239 dynamics on stable ART and after ART cessation in rhesus macaques (RMs). Among the RMs with full CD8+ T cell depletion in both blood and tissue, there were no significant differences in the frequency of viral blips in plasma, the number of SIV RNA+ cells and the average number of RNA copies/infected cell in tissue, and levels of cell-associated SIV RNA and DNA in blood and tissue relative to control-treated RMs during ART. Upon ART cessation, both CD8+ T cell-depleted and control RMs rebounded in fewer than 12 days, with no difference in the time to viral rebound or in either the number or growth rate of rebounding SIVmac239M barcode clonotypes. However, effectively CD8+ T cell-depleted RMs showed a stable, approximately 2-log increase in post-ART plasma viremia relative to controls. These results indicate that while potent antiviral CD8+ T cell responses can develop during ART-suppressed SIV infection, these responses effectively intercept post-ART SIV rebound only after systemic viral replication, too late to limit reactivation frequency or the early spread of reactivating SIV reservoirs.

摘要

为了确定 CD8+T 细胞反应在抗逆转录病毒治疗(ART)期间和之后对 SIV 再激活的控制的贡献,我们使用抗 CD8β 单克隆抗体对恒河猴进行了长期的 CD8+T 细胞耗竭,以确定其对稳定接受 ART 治疗和停止 ART 治疗后的 SIVmac239 动力学的影响。在血液和组织中完全耗尽 CD8+T 细胞的恒河猴中,在血浆中病毒斑点的频率、SIV RNA+细胞的数量和组织中 RNA 拷贝/感染细胞的平均数量、以及血液和组织中细胞相关 SIV RNA 和 DNA 水平方面,与接受对照治疗的恒河猴相比,没有明显差异。停止 ART 治疗后,CD8+T 细胞耗竭组和对照组恒河猴在不到 12 天内都出现了反弹,病毒反弹的时间、反弹的 SIVmac239M 条码克隆型的数量或增长率均无差异。然而,实际上 CD8+T 细胞耗竭组恒河猴在 ART 后血浆病毒血症中稳定地增加了约 2 个对数级,相对于对照组。这些结果表明,虽然在 ART 抑制的 SIV 感染期间可以产生有效的抗病毒 CD8+T 细胞反应,但这些反应只有在系统性病毒复制后才能有效地阻止 ART 后的 SIV 反弹,为时已晚,无法限制再激活频率或再激活 SIV 储存库的早期传播。

相似文献

4
Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers.
PLoS Pathog. 2016 Sep 15;12(9):e1005879. doi: 10.1371/journal.ppat.1005879. eCollection 2016 Sep.
9
CD8+ lymphocyte control of SIV infection during antiretroviral therapy.
PLoS Pathog. 2018 Oct 11;14(10):e1007350. doi: 10.1371/journal.ppat.1007350. eCollection 2018 Oct.

引用本文的文献

1
Autovaccination revisited: potential to boost antiviral immunity and facilitate HIV-1 cure/remission in children.
Curr Opin HIV AIDS. 2025 May 1;20(3):271-278. doi: 10.1097/COH.0000000000000924. Epub 2025 Mar 19.
2
Intravenous BCG-mediated protection against tuberculosis requires CD4+ T cells and CD8α+ lymphocytes.
J Exp Med. 2025 Apr 7;222(4). doi: 10.1084/jem.20241571. Epub 2025 Feb 6.
3
Enhancing broadly neutralising antibody suppression of HIV by immune modulation and vaccination.
Front Immunol. 2024 Nov 7;15:1478703. doi: 10.3389/fimmu.2024.1478703. eCollection 2024.
4
Immunotoxin-mediated depletion of Gag-specific CD8+ T cells undermines natural control of SIV.
JCI Insight. 2024 Jun 17;9(14):e174168. doi: 10.1172/jci.insight.174168.
6
Recent advances on anti-HIV chimeric antigen receptor-T-cell treatment to provide sustained HIV remission.
Curr Opin HIV AIDS. 2024 Jul 1;19(4):169-178. doi: 10.1097/COH.0000000000000858. Epub 2024 May 1.
9
Preferential selection of viral escape mutants by CD8+ T cell 'sieving' of SIV reactivation from latency.
PLoS Pathog. 2023 Nov 30;19(11):e1011755. doi: 10.1371/journal.ppat.1011755. eCollection 2023 Nov.
10
Recent advances in CD8 T cell-based immune therapies for HIV cure.
Heliyon. 2023 Jun 20;9(6):e17481. doi: 10.1016/j.heliyon.2023.e17481. eCollection 2023 Jun.

本文引用的文献

1
SARS-CoV-2 infection protects against rechallenge in rhesus macaques.
Science. 2020 Aug 14;369(6505):812-817. doi: 10.1126/science.abc4776. Epub 2020 May 20.
2
4
Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8 cells.
Nature. 2020 Feb;578(7793):154-159. doi: 10.1038/s41586-020-1946-0. Epub 2020 Jan 22.
5
Predictors of SIV recrudescence following antiretroviral treatment interruption.
Elife. 2019 Oct 25;8:e49022. doi: 10.7554/eLife.49022.
7
Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology.
Front Immunol. 2019 Sep 10;10:2109. doi: 10.3389/fimmu.2019.02109. eCollection 2019.
8
The Landscape of Persistent Viral Genomes in ART-Treated SIV, SHIV, and HIV-2 Infections.
Cell Host Microbe. 2019 Jul 10;26(1):73-85.e4. doi: 10.1016/j.chom.2019.06.005.
9
CD8+ lymphocyte control of SIV infection during antiretroviral therapy.
PLoS Pathog. 2018 Oct 11;14(10):e1007350. doi: 10.1371/journal.ppat.1007350. eCollection 2018 Oct.
10
Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound.
Nat Med. 2018 Sep;24(9):1430-1440. doi: 10.1038/s41591-018-0130-7. Epub 2018 Aug 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验